Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2009/062537external-prioritypatent/WO2010037715A1/en
Application filed by Novartis AgfiledCriticalNovartis Ag
Publication of TN2011000124A1publicationCriticalpatent/TN2011000124A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
The invention provides methods for modulating, e.g., antagonizing, the activity of the Hedgehog signaling pathway, and for treating Hedgehog related disorders such as cancers (e.g., medulloblastoma). In particular, the invention provides methods for inhibiting aberrant growth states resulting from phenotypes such as Ptch Io ss-of- function, Hedgehog gain-of- function, smoothened gain-of- function or GIi gain-of-function by administering to a mammal combinations of Smoothened inhibitors (e.g., a compound of Formula I, Formula II, or Formula III, or any of the compounds listed herein or incorporated by reference) and cholesterol biosynthesis pathway inhibitors (e.g., statins), GIi inhibitors, and/or Phosphatidylinositol 3-kinase (P13K) inhibitors.
TN2011000124A2009-09-282011-03-08Smoothened antagonism for the treatment of hedgehog pathway-related disorders
TN2011000124A1
(en)